# A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

> **NCT05282953** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kiora Pharmaceuticals, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Choroideremia
- Non-Syndromic Rod-Dominant Inherited Retinal Diseases

## Interventions

- **DRUG:** KIO-301

## Key facts

- **NCT ID:** NCT05282953
- **Lead sponsor:** Kiora Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-10
- **Primary completion:** 2023-08-10
- **Final completion:** 2026-03-24
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282953, "A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05282953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*